SHBG (sex hormone-binding globulin) is a carrier protein for sex hormones like estrogen and testosterone. During menopause, estrogen levels drop, which can alter SHBG production and increase free, active testosterone. Low SHBG levels are associated with a higher risk of metabolic syndrome, insulin resistance, and type 2 diabetes—conditions that become more common after menopause. However, SHBG itself is not a therapeutic agent. No robust clinical trials show that raising SHBG (e.g., through diet or medication) directly alleviates menopausal symptoms such as hot flashes or mood changes. Hormone replacement therapy (HRT) remains the gold standard for severe symptoms. SHBG may serve as a biomarker to assess metabolic risk, but focusing solely on SHBG as a 'helper' is not scientifically supported. The evidence is mostly observational; randomized controlled trials are lacking. Therefore, while SHBG is relevant in the context of menopause, it should not be considered a treatment or solution.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-290f5df247f360170c47030a